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Η αποτίμηση της αξίας της φαρμακευτικής 
καινοτομίας σε μια εποχή αυξανόμενης λιτότητας
Μαίρη Γείτονα, Πανεπιστήμιο Πελοποννήσου
ABSTRACT
In this paper an overview of the rewarding 
innovation pharmaceutical regulatory systems 
has been presented, focusing on the emerging 
role of innovation and health technology 
assessment (HTA). Ιn a time of political and 
financial turmoil, benefits could be obtained 
through the pooling of resources and 
experiences among various countries. For this 
purpose, recent major pharmaceutical reforms 
in Greece have been critically discussed taking 
into consideration the dynamic and complex 
environment among cost containment measures 
and the recent implementation of HTA in 
combination with some of the critical factors 
that influence today’s key decision makers, such 
as the economic crisis, increasing austerity as 
well as political and international pressures.  
KEY  WORDS: HTA, innovation, pharmaceutical 
pricing and reimbursement, Greece.
ΠΕΡIΛΗΨΗ
Το άρθρο παρουσιάζει τα επικρατέστερα συ-
στήματα ρύθμισης της αγοράς φαρμάκου δι-
εθνώς, δίνοντας έμφαση σε αυτά που επιβρα-
βεύουν την καινοτομία και αναδεικνύουν το 
σημαντικό ρόλο της Αξιολόγησης της Τεχνολο-
γίας Υγείας (ΑΤΥ). Η ανασκόπηση των διεθνών 
προτύπων κρίνεται ιδιαίτερα σημαντική για την 
παρούσα πολιτική και οικονομική συγκυρία 
που αντιμετωπίζει η χώρα. Γι αυτό το σκοπό, 
στο άρθρο επιχειρείται κριτική προσέγγιση των 
πρόσφατων μεταρρυθμίσεων στην Ελλάδα, 
πρώτον ως προς την επίτευξη ή μη των στό-
χων των πολιτικών συγκράτησης και ελέγχου 
των δαπανών υγείας, και δεύτερον ως προς τα 
δυνητικά οφέλη που θα προκύψουν από την 
εφαρμογή της ΑΤΥ στη χώρα.
ΛΕΞΕΙΣ-ΚΛΕΙΔΙΑ: Αξιολόγηση Τεχνολογίας 
Υγείας (ΑΤΥ), καινοτομία, τιμολόγηση και 
αποζημίωση φαρμάκων, Ελλάδα.
Κοινωνική Συνοχή και Ανάπτυξη 2012 7 (1), 39-51
Social Cohesion and Development 2012 7 (1), 39-51
1. Introduction
T he varying nature and emerging complexity of health technologies, in combination with limited healthcare resources, have resulted in efforts to deliver cost-effective healthcare, 
improve Research and Development (R&D) and sustain the entrepreneurship and manufacturing by 
maintaining the societal benefit of the healthcare sector. Growth in demand for healthcare is strong 
and expenditure is increasing due to the continuing increasing demand for health technologies 
and especially for pharmaceuticals.
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In Europe, the research-based pharmaceutical industry is one of the leading high technology 
industries, amounting to about 19% of global business R&D investments and about 3.5% of the 
total EU manufacturing added value (EFPIA, 2011). The European pharmaceutical market is highly 
fragmented and strictly driven by cost containment and regulatory policies that many times prevent 
rewarding innovation. This refers as the reason behind the US pharmaceutical market dominates 
over the European, given that 65% of sales of new medicines marketed since 2002 are generated 
on the US market, compared to 24% on the European market (IMS, 2011). 
In an era of increasing austerity, the fact that pharmaceutical industry is one of Europe’s best 
performing high-technology sectors should always be taken into consideration. It is increasingly 
important to achieve a balance between affordable healthcare and the use of innovative health 
technologies, at national, European and international level. In this context, the aim of paper is 
to make an overview of the value-based regulatory systems rewarding innovation, widely used in 
the EU. The increase in the use of health technology assessment (HTA) and its impact on today’s 
key decision makers are also discussed. Finally, a critical review is made regarding the major 
pharmaceutical reforms taken place in Greece, giving emphasis in the reasoning behind the failure 
or the success of the policies implemented. 
2. The value of pharmaceutical innovation 
 
I nnovation in pharmaceuticals plays a critical role in both the industrial and health fields. A drug can be considered a pharmaceutical innovation only if it meets otherwise unmet or inadequately 
met health care needs. Pharmaceutical innovations create value to society by generating 
improvements in patient health (net of treatment risks) that were previously unattainable (Morgan 
et al., 2008). There is growing evidence at macro and micro-economic level regarding the added 
value of medicines in the healthcare sector, not only in terms of global cost savings but also in terms 
of increasing the quality of care. Medicines not only improve health status, but also generate savings 
by substantially reducing costs through the substitution of hospital care etc. Therefore, decision 
makers should take into consideration the overall therapeutic and economic value of medicines
Medicines remain the prime target of cost containment policies, despite the fact that on 
average pharmaceutical spending accounts for only 16.6% of total health expenditure in Europe 
(EFPIA, 2011). Although rises in pharmaceutical spending are observed, recent increases in health 
spending are not primarily caused by increases in spending on pharmaceuticals. Since 2005 the 
contribution towards total increases in health spending attributed to pharmaceuticals is 17.3% in 
Canada, 13.8% in France, 15.1% in Germany, 5.6% in Italy, 14.0% in Spain, 5.4% in the United 
Kingdom and 10.9% in the United States (US Department of Trade, 2004; OECD Health Data, 
2010). Hence, reforms or cost containment policies focusing on pharmaceutical expenditure alone 
are unlikely to achieve significant cost savings and achieve their targets.
Innovation remains a predictor for increasing healthcare expenditures. Rational criteria in terms 
of safety, efficiency, effectiveness and equity, used in the pricing and reimbursement mechanisms 
should provide incentives and reward innovation. Certainly, it is very difficult to measure spill over 
effects of medical technology in economic terms, despite the fact that a number of studies have 
demonstrated the health gains and cumulative benefits of such innovation (Kanavos et al.,2010). 
The benefits of pharmaceutical innovation should include clinical/therapeutic benefits, quality of 
life benefits, and socio-economic benefits. According to the international literature, there are 
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different criteria required by EU regulatory authorities in order to assess new technologies for 
pricing and reimbursement purposes. The benefits should be evident, since achieving incremental 
innovation requires significant investments that can be seen as a challenge for healthcare systems. 
Some countries like the United Kingdom, Finland and the Netherlands refer to cost-effectiveness 
and patients’ quality of life criteria to determine the real value of a medicine while other countries, 
such as Austria, Belgium, Denmark, Ireland, Italy and Portugal take into account a variety of socio-
economic criteria. But there are still some European countries, such as Greece, in which healthcare 
policies are short term and they do not yet take into consideration the overall therapeutic and 
economic value of the use of new technologies (Abel-Smith and Mossialos,1994; Dickson,1992; 
Jonsson,1994; Kanavos, 2002; Valasco-Garrido et al.,2008; Mousiama et al.,2001; Liaropoulos and 
Kaitelidou, 2000; Geitona and Kanavos, 2010.
3. Pricing and reimbursement practices in EU countries 
I n most countries, the pharmaceutical market is one of the most heavily regulated sectors, since governmental regulation takes into consideration healthcare market failures related to the 
safety, equity, accessibility and cost containment concerns. The rationale behind state intervention 
is focused on the fact that health policy decision makers attempt to ensure the efficient and 
equitable access to medicines, provide adequate incentives for innovation, and control total 
health /or and pharmaceutical expenditure. Measures taken for controlling the performance of 
pharmaceutical markets are complex and often conflicting since they are usually targeting at 
different and multiple actors such as the manufacturers, wholesalers, physicians, pharmacists, 
patients and the third-party-payers. Pharmaceutical market regulations are mainly focusing on 
the improvement of the effectiveness, safety and quality of pharmaceuticals, in combination 
with their rational use and control expenditure. Alternative regulation mechanisms include well-
defined, structured and systematic actions induced by regulators in order to affect the rules and 
the functioning of the pharmaceutical market by changing the multiple agents’ behaviour (Chen, 
1999; Kanavos et al., 2010). 
In economic theory terms, governmental regulation refers to the measures taken usually 
distinguished between the supply and demand-side. The demand side of pharmaceuticals refers 
to the patient/consumer, the prescriber and the pharmacist and takes into consideration that the 
respective healthcare provision is paid by third party payers. It is evident that in the EU countries, 
the share of drugs’ expenditure financed by third-party payers accounts for over 75% of the total 
market (Mrazek, 2002). The supply side of pharmaceutical markets is determined absolutely by all 
agents involved in the drugs’ production.
The demand side interventions are aimed at changing the behaviour of healthcare 
professionals and patients. Clinical and prescription guidelines focusing on the monitoring and 
changing of prescribing patterns, the implementation of pharmaceutical budgets for reinforcing 
cost-consciousness and generics substitution are the most common measures taken for controlling 
the cost of prescribed treatments, promote a more rational use of medicines while maintaining 
the quality. As far as demand side interventions aiming at affecting patients’ behaviour, cost-
sharing, co-payments and co-insurance practices are included. It is noteworthy to mention that 
patients’and health professionals’ behaviour change is primarily affected by third party payers and 
the reimbursement status of each product category. The definition of the amount of the price to 
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be paid by the third-party payer, already mentioned as reference pricing system, as well as the 
adoption of positive and negative lists are practices closely associated with patients’ cost-sharing 
and co payments reimbursing mechanisms (Lopez- Casanovas and Puig-Junoy, 2000; Kanavos, 
2002; Helin-Samivaara et al., 2003; Gray,2006; Espin and Rovira, 2007; Tsiantou at al., 2009; 
Geitona and Kanavos 2010).
In most EU countries, supply side interventions include price regulation, direct expenditure and 
profit control as well as tax benefits. More analytically, price regulation refers to the administrative 
or statutory pricing, such as price caps, positive or negative reimbursement lists, etc. In situations 
of information asymmetry, as in the case of pharmaceutical products, the exercise of the price 
setting is complicated compared to the other goods whereas perfect information dominates in the 
consumption process. When price regulation is based on the product’s cost plus a certain profit 
margin of the manufacturer’s, refers to the cost-plus pricing system. Additionally, price regulation 
can be referred to the referencing pricing system which is based on the prices for the same product 
in other countries or for the same indications of similar treatments. Another price regulation 
mechanism derives from economic evaluations and is usually used for pricing and reimbursement 
decisions (Espin and Rovira, 2010; Kanavos et al., 2010). 
Direct expenditures controls are also introduced in order to contain pharmaceutical 
expenditures through the set up of mandatory or negotiated discounts in the drug’s price, as well 
as rebates related to a specified proportion of the sales made by a manufacturer to the purchaser 
over a given time period (i.e Germany, Ireland, Spain). Similar is also the payback control system 
which serves as a risk-sharing mechanism requiring manufacturers to return a part of their revenue, 
if sales exceed a previously determined target. Additionally, price-volume agreements are applied 
to specific new products, where the price agreed is conditional to the expected number of units 
sold. (i.e France, Spain). Profit control refers to a system applied in the UK for the sales of branded 
medicines to the NHS and tax benefits are related to the manufacturer’s investment in R&D (i.e 
Belgium) (Kanavos, 2002; Simoens et al., 2005; Espin and Rovira, 2007).
Among other systems of supply-side regulation for price setting, the Value Based Pricing 
(VBP) and the External Price Referencing (EPR) systems are currently used extensively to inform 
decisions on pricing and reimbursement of pharmaceuticals. VBP integrates the value into the 
price of medicines in order to reward products that have better outcomes and to encourage future 
innovation in the development of new therapeutic agents. VBP can serve as a validation mechanism 
of new technologies, enable governments to make decisions driven by value and provide health 
professionals and patients the information needed to make the best treatment choices (Sorenson 
et al. 2008; Kanavos et al., 2010; Espin and Rovira, 2010). 
External or International Price Referencing (EPR) system involves the selection of a basket of 
countries, which can change over time, to compare pharmaceutical prices and create a reference 
price (RP) for a country. It can be used for price negotiation and setting within a country as well 
as for reimbursement and market authorisation purposes. In addition, it provides a benchmark for 
negotiations between industry and health insurance organisations. Combination of both systems 
(VBP and EPR) can be applied for setting pharmaceutical pricing and reimbursement within a 
country. It is important to note that the process of selection of the above mentioned pricing 
systems is complex. In VBP the definition of value is the key factor and the value determination 
should be based on the cost effectiveness analysis (CEA) and more precisely, on the incremental 
cost effectiveness ratio (ICER). The greatest difference between VBP and EPR, is that VBP relies 
on a combination of scientific and social value judgements to inform pricing and reimbursement 
decisions, whereas EPR borrows these indirectly from other countries (Kanavos et al., 2010). 
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4. The emerging role of HTA
H ealth Technology Assessment (HTA) has come under focus in the last three decades and has become a crucial part of the decision making process in the healthcare sector. HTA is a 
multidisciplinary process that summarises information about the medical, social, economic and 
ethical issues related to the use of a health technology in a systematic, transparent, unbiased, 
robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient 
focused and seek to achieve best value (www.eunethta.eu). HTA networks at EU level are aiming to 
contribute to the generation of HTAs to inform policy and healthcare decision making in European 
countries so that new health technologies can be adopted and obsolete technologies abandoned in 
a well-informed and robust manner, hence bringing about high quality, safe, accessible, sustainable, 
ethical and efficient health care for citizens across Europe. The partners in the EUnetHTA Collaboration 
share the overarching values of the European Union for health systems such as universality, access to 
good quality care, equity and solidarity (Valasco-Garrido et al.,2008).
In practical terms, the role of HTA is to provide informed decisions aiming at allocating 
resources within the healthcare sector in order to improve the efficiency in healthcare. There are 
many variations in the practice of HTA. In some cases, HTA is linked to reimbursement and third 
party payers’ decision making; in others to clinical guidelines and disease management, etc. HTA is 
also carried out at different levels of government, and there are considerable variations in the level 
of stakeholder involvement, in the methodology used and in the quality of studies. In addition, 
in most countries economic evaluations studies are increasingly included in HTA despite their 
differentiations observed in the methodologies used, the type of the analysis and the data used. 
For this purpose specific guidelines are also available in economic evaluation studies. 
HTA bodies are responsible for assessing the economic, social, organisational and ethical 
implications of a given technology which usually refers to drugs, medical devices and procedures. 
They aim to improve the quality and safety of healthcare in a context of continuous medical progress, 
by advising decision makers, producing guidelines for health professionals, certifying healthcare 
organisations, developing diseases’ management and informing health professionals, patients and 
the public. Today, HTA is used to assess new technologies before or after their establishment 
on the market. The challenges that lie ahead include the need to provide advice in a timely 
and transparent manner, by using multi-disciplinary approaches and taking into consideration 
stakeholders’ issues. HTA analyses must not be restricted to individual product medical added 
value but they should make reviews beyond it. HTA studies on innovative technologies should be 
used at the national level in the formulation of national health policies, given that costs and values 
differ among countries. 
It is well known that most European Union member states have established responsible bodies 
for publishing pricing and reimbursement (P&R) guidelines, since price setting remains a national 
health policy issue. In this context, the establishment of HTA agencies worldwide is targeting to 
inform decisions aimed at allocating resources within the healthcare sector (Zentner at al., 2005; 
Yfantopoulos, 2008; Kanavos et al., 2010a; Wilsdon and Serota 2011). Decisions about third party 
payers and stakeholders are the most important target for HTA agencies in order to improve the 
allocative efficiency of healthcare. The criteria used for assessment and the role of global HTAs in 
P&R as well as in market access decisions are presented in the Table 1. 
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In the UK the National Institute for Clinical Excellency (NICE), established in 1999, undertakes 
a more-rigorous approach to economic evaluation. The role of NICE is to make recommendations to 
health professionals on the economic appraisal of new and existing technologies, the development 
of clinical guidelines and the specification of audit technologies. Nowadays, NICE contribution 
is very significant, since it has made restrictive or negative rulings on 63% of all drugs examined 
data. In 2003, the Institute for Quality and Efficiency in Health Care (IQWIG) was established in 
Germany aiming to evaluate the current state of medical knowledge on diagnostic and therapeutic 
schemes for selected group of diseases, the quality and efficiency of services provided by the 
statutory health insurance and drugs’ effectiveness. IQWIG is also responsible for the development 
of evidence based guidelines and recommendations for disease management as well as for the 
dissemination of information on evidence-based therapies. IQWIG contribution is substantial 
since it reported no proven benefit in 73% of all drugs examined. 
Adversely, the role of the SBU in Sweden, established in 1987 and in 1992 commissioned as an 
independent public authority, does not make any decisions concerning approval or reimbursement 
of drugs, and does not have a supervisory function. However, despite its relative lack of power, SBU 
has made a substantial contribution to improvements in the healthcare system. In a survey carried 
out in 2002, 81% of physicians stated that they obtained a practical benefit from SBU reports. 
Additionally, SBU projects on the pre-operative routines and the management of mild head injury 
led to annual savings of about €24 million and €4 million respectively. Furthermore, the report 
concerning the non evidence that calcium and vitamin D supplements prevent osteoporosis among 
women under the age of 80, revealed a potential saving of €3.2 million (www.sbu.se).
Nowadays, a number of countries in Europe actively use health economic evaluations and 
have established HTA bodies. They have also set up pharmaco-economic guidelines to be used 
in the decision-making process. Some of these countries are the UK, Netherlands, Finland, 
Portugal, Sweden, Denmark, Ireland, Switzerland, France, Italy, Estonia, Poland, Hungary etc. The 
administrative structure of the healthcare system affects significantly the type and the function of 
HTA in each county. In highly de-centralised countries, such as in Sweden, there are more than one 
body while in others HTA decisions are taken at national level. It is worth to mention that the lack 
of a systematic process for the selection of technologies for evaluation as well as the no evident 
link between regulatory and HTA bodies refer among the most significant drawbacks. 
In summary, a global perspective of HTA may offer a predictable environment for long-term 
investment to the industry, clarity of roles & responsibilities to decision makers and assessments 
based on the added therapeutic value to patients. International collaboration among various HTA 
agencies should be reinforced through the already existing network of competent national and 
international agencies. The enforcement of the EUnetHTA Collaboration is very useful since it 
provides systematic information on the use of best available evidence, common methodological 
and process standards as well as common review processes.
5. Medicinal market regulation in Greece
D rugs’ market regulation operates under the guidance of the Ministry of Health and Social Solidarity (MoH) in accordance to the EU legislation. The process regarding drugs’ market 
authorisation is operating under the responsibility of the National Drug Organization (EOF), and 
pricing process under the responsibility of the Pricing Committee at the MoH. For drugs’ approval, 
pharmaceutical companies are required to submit the product’s dossier to the National Drug 
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Organization (EOF) and for pricing setting to the Ministry’s respective Committee. The pricing 
Committee is responsible for the price determination as well as for the drugs’ price bulletins 
publication. Prices’ setting takes into account the wholesale prices of imported and locally 
manufactured or packaged products as well as various other criteria. 
In Greece, health authorities have always applied regulatory controls on the supply-side with 
emphasis on prices’ reductions targeting to control the growth of pharmaceutical expenditure. 
Short-term measures taken to reduce pharmaceutical expenditure failed to deal with rising 
healthcare budgets and most importantly hampered innovation. In that sense, technology up to 
now has been considered as a cost driver increasing health service intensity, excess inflation and 
the cost of treatment, since the overall benefits of pharmaceutical innovation are not yet taken 
into consideration. 
Last two decades, three major reforms (1998, 2006 and 2010) have been implemented 
targeting at pharmaceuticals’ control. The first reform refers to the introduction of a positive 
reimbursement list and a reference pricing system based on the lowest price among the 15 EU 
countries. Although based on legislation the principle criterion for the inclusion of a drug in 
the list was its therapeutic value, which was based on the severity of the disease, the product’s 
effectiveness/safety ratio, the availability of alternative treatments and the target population, the 
only inclusion criterion was the daily treatment cost. In order for a product to be included in the 
positive list, its average cost of daily treatment should be equal to or lower than the reference price 
of each therapeutic category. Both measures didn’t achieve their goals and the country reference 
pricing system has been judged by the Council of State as unconstitutional. More importantly, 
positive list failed because it restricted patients’ access to new and more effective drugs, given that 
it took years to update the list with negative impact on long-term innovation. Drugs withdrawals 
from the market and shortages have been reported while parallel trade and exports increased. 
Also, patients’ co-payments had not a significant impact on controlling expenditures due to low 
prices of pharmaceuticals in the country. 
The second major reform, in 2006, refers to the abolishment of the existing positive list aiming 
at the reimbursement of all medicines except OTCs and lifestyle drugs (not defined till 2011). In 
addition, a new pricing system was introduced based on the average of the three lowest European 
prices, of which two were calculated from the former 15 European Member States plus Switzerland 
and one from the new EU members (Yfantopoulos, 2008). Also, the 2006 reform introduced a 
rebate system paid by the pharmaceutical companies to the Social Security Funds (SSF). Again, 
the above cost containment measures didn’t achieve their goals since the rebate system partially 
operated and pharmaceutical expenditures were continuously increasing due to the inability of 
controlling the volume of prescribed drugs as well as changing physicians’ prescribing behaviour 
(Geitona and Xaplanteris, 2010).
It is worth mentioning that the 1998 and 2006 reforms appeared inefficient given that 
pharmaceutical expenditures were continuously increasing, regardless of the introduction or the 
abolishment of the positive list. The reasoning behind the expenditure rise is that the supply side 
measures taken were solely focused on prices’ control and measures targeting at the demand side 
were totally missing.
In 2010 and Greece being under the economic crisis and EU and IMF inspection, the 
government adopted tough austerity measures in order to: 
• Cut government spending, 
• Reduce the size of the public sector, 
• Decrease tax evasion - increase tax collection, 
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• Control health spending - reform healthcare and pension systems 
• Improve competitiveness through structural reforms to the labor and product markets. 
In this context, the government legislated in 2010 a third reform on pharmaceuticals. This 
time the government implemented both supply and demand side measures in order to reduce 
pharmaceutical spending. Again, a new positive reimbursement list was introduced by classifying 
the drugs in ATC4 clusters and the drug’s daily treatment cost should not exceed the average cost 
of each therapeutic category which was comprised by branded and generic products. Any excess 
would be paid back as a rebate for enlistment. More importantly, in the criteria of the reimbursement 
list there was a provision for accepting a 20% price premium for innovative medicines with the 
submission of pharmacoeconomics studies. In addition, this reform included numerous cost-
containment measures targeting to control NHS hospitals’ pharmaceutical expenditure through 
the introduction of hospital formularies, therapeutic protocols/guidelines, patients’ electronic 
prescribing, drug tenders, changing of physicians’ prescription patterns and generic substitution. 
Also, the creation of an integrated information technology (IT) system intra and across hospitals 
as well as the establishment of a HTA body have been announced. More analytically, a set of 
measures have been legislated targeting at hospital spending control such as the centralised public 
procurement of medical supplies, the modernisation of hospital accounting and billing systems, 
bookkeeping of medical supplies and monitoring activity in NHS facilities, timely invoicing etc. 
As about the establishment of the HTA body it aimed to evaluate new technologies in health, 
therapeutic interventions, clinical practices, and disease management.
Similar measures have also been applied to social security funds (SSF) for the reduction of 
their expenses with emphasis given in the creation of an integrated electronic processing system 
for controlling the prescriptions and diagnostic tests within all SSFs. As of 2011 the 4 key SSFs 
covering 90% of the Greek insured population were unified to form EOPYY with increased 
negotiating power.
It should be mentioned that although the implementation of these measures has not yet been 
completed, it seems to be successful in controlling spending (figure 1), since total pharmaceutical 
expenditure decreased more than € 2 billion in 2010-2011, both outpatient and hospital, exceeding 
the troika target which was €2 billion . However, other cost drivers within the hospital sector 
remained uncontrolled and offset major savings coming from drugs and other supplies (Figure 2).
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2011 drug savings vs 2010 are squandered due to increased costs of outsourcing and 
other liabilities
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In addition, the price premium never operated and cost-effectiveness criteria have been 
excluded from the list, although they had already been announced by the MoH. Hopefully, in 
November 2011 the Greek HTA agency began to operate, the so called National Centre for 
Evaluation of Quality and Technology in Healthcare. It is expected that investment in HTA would 
offer long term benefits related to improvements in healthcare access and outcomes as well as 
rationality in resources allocation. Potential benefits of the HTA in Greece should be:
• Establishment of cost-effective prescribing policies
• Reinforcement of decision making based on costs and benefits rather than cost cutting
• Help purchasers to set priorities
• Providers’ choice of the most cost-effective treatment techniques -practices
• Recommendations can be used as criterion for reimbursement acceptance
• Maximization of health gains from a finite budget or/and maximize of outcomes to input 
constraints
• Reallocation of resources from less to more productive uses.
Furthermore, the Greek HTA Centre may provide consultations regarding the short- and long-
term social and economic consequences of the use of new technologies and make recommendations 
on their effective and efficient use mainly for reimbursement purposes. It is believed that with 
the 2010-11 measures taken, the government will meet IMF proposed targets and savings, 
rationalize healthcare investments and ensure economic sustainability especially of the insurance 
organizations. By this way, the NHS primary goals such as the improvement in the quality of 
healthcare delivery, the universal access and the increase in the productivity of healthcare sector 
will be achieved
6. Concluding remarks 
I n a time of political and financial turmoil, benefits could be obtained through the pooling of resources and experiences among various countries. In this paper an overview of the rewarding 
innovation regulatory systems has been presented, systems that are widely used in the EU and 
specific OECD countries based on the assumption that clinical and social value judgements among 
countries could be suited in another country. However, it has been seen that each EU country has 
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a specific set of requirements and local adaptations of HTA which are not as straight forward, 
as they seem. Different countries utilize different levels of complexity and processes as well as 
different advantages, limitations and impact key variables such as price/reimbursement, coverage 
and access, assessment of value and rewarding of innovation (Kanavos et al.,2002). 
For this purpose, recent major pharmaceutical reforms in Greece have been critically discussed 
in this paper, taking into consideration the dynamic and complex environment among cost 
containment measures and the implementation of health technology assessment in combination 
with some of the critical factors that influence today’s key decision makers, such as the economic 
crisis, increasing austerity as well as political and international pressures. 
In brief and critically thinking, it should be mentioned that the implementation of cost 
containment measures were necessary in the country in order to stabilize or/and reduce health care 
& pharmaceutical expenditure. The above measures applied were usually short term and based 
on price cuts rather than on value assessment and volume controls, and were mostly restricted to 
medicinal products. 
The traditional criteria in terms of safety, efficiency, effectiveness and equity are almost 
always used in the pricing and reimbursement mechanisms but they very seldom provide incentives 
and reward innovation. If a product offered superior or/and marginal therapeutic benefit, it was 
difficult to justify a price premium relative to its competitors. In that sense, the allocation of health 
resources was always based on the maximum investment required with unknown or never assessed 
benefits, since reimbursement price was negotiated on the basis of a variety of factors, excluding 
pharmacoeconomic criteria. By this way, the therapeutic value of a product could not be rewarded, 
since economic evaluation and HTA was out of any consideration.
The 2010 -11 reform regarding the creation of HTA agency in Greece seems to be very 
promising since it would speed up decision making and lead to the development of evidence based 
policies. Hence the existence of real-world evidence would demonstrate the value of medicines 
and other new technologies in the real world. It is believed that Greek government and IMF 
expectations will be fulfilled due to long term targeting and acceptance of value based pricing and 
reimbursement practices. Hence, long-term economic accountability may sustain entrepreneurship 
and reinforce innovation and employment which are imperative at a time of economic recession 
and uncertainty that Greece is facing nowadays. 
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